Palvella Therapeutics Statistics
Share Statistics
Palvella Therapeutics has 11.04M
shares outstanding. The number of shares has increased by null%
in one year.
| Shares Outstanding | 11.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 526 |
| FTD / Avg. Volume | 0.65% |
Short Selling Information
The latest short interest is 251.36K, so 2.24% of the outstanding
shares have been sold short.
| Short Interest | 251.36K |
| Short % of Shares Out | 2.24% |
| Short % of Float | 2.77% |
| Short Ratio (days to cover) | 2.31 |
Valuation Ratios
The PE ratio is -1.53 and the forward
PE ratio is null.
Palvella Therapeutics's PEG ratio is
0.
| PE Ratio | -1.53 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.43 |
| P/FCF Ratio | -2.46 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Palvella Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.33,
with a Debt / Equity ratio of 0.
| Current Ratio | 7.33 |
| Quick Ratio | 7.33 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.26 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,245,285.71 |
| Employee Count | 14 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by null% in the
last 52 weeks. The beta is -23.17, so Palvella Therapeutics's
price volatility has been lower than the market average.
| Beta | -23.17 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 24.86 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.04 |
| Average Volume (20 Days) | 80,319 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.1M |
| Net Income | -17.43M |
| EBITDA | -13.12M |
| EBIT | -13.12M |
| Earnings Per Share (EPS) | -7.83 |
Full Income StatementBalance Sheet
The company has 83.6M in cash and 0 in
debt, giving a net cash position of 83.6M.
| Cash & Cash Equivalents | 83.6M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -93.73M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -10.84M
and capital expenditures 0, giving a free cash flow of -10.84M.
| Operating Cash Flow | -10.84M |
| Capital Expenditures | n/a |
| Free Cash Flow | -10.84M |
| FCF Per Share | -4.87 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
